Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
The leukemic stem cells in patients with chronic myeloid leukemia (CML) are well known to
be clinically resistant to conventional chemotherapy and may also be relatively resistant to …
be clinically resistant to conventional chemotherapy and may also be relatively resistant to …
[HTML][HTML] The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation
SW Cowan-Jacob, G Fendrich, PW Manley, W Jahnke… - Structure, 2005 - cell.com
The regulation of the activity of Abl and Src family tyrosine kinases is mediated by
intramolecular interactions between the SH3, SH2, and kinase (SH1) domains. We have …
intramolecular interactions between the SH3, SH2, and kinase (SH1) domains. We have …
[PDF][PDF] Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer cell, 2010 - cell.com
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
[HTML][HTML] Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival …
NP Shah, DW Kim, H Kantarjian, P Rousselot… - …, 2010 - ncbi.nlm.nih.gov
Background Dasatinib 100 mg once daily achieves intermittent BCR-ABL kinase inhibition
and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant …
and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant …
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavarria… - Blood, The Journal …, 2008 - ashpublications.org
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
[HTML][HTML] Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic …
JE Cortes, M Baccarani, F Guilhot… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in
Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic …
Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic …
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
A Hochhaus, P La Rosée - Leukemia, 2004 - nature.com
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
H Kantarjian, M Talpaz, S O'Brien, G Garcia-Manero… - Blood, 2004 - ashpublications.org
Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …
Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update
Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …